Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.45 |
| ▸ | NR1I3 | Q14994 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 6/20 | 0.43 |
| ▸ | MMP3 | P08254 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14037479 | 0.90 | NR1I3 (0.47) | CA12CA1CA9NR1I3MAPT | |
| SCHEMBL1114945 | 0.85 | RAB9A (0.56) | CA12CA1CA9CYP17A1NR1I3 | |
| SCHEMBL30476642 | 0.83 | NPC1 (0.53) | CA12CA1CA9NR1I3MAPT | |
| SCHEMBL19996133 | 0.83 | NPC1 (0.53) | CA12CA1CA9NR1I3MAPT | |
| SCHEMBL15022432 | 0.81 | MAPT (0.52) | CA12CA1CA9CYP17A1NR1I3 | |
| SCHEMBL7046627 | 0.81 | CA12 (0.47) | CA12CA1CA9CYP17A1NR1I3 | |
| SCHEMBL31169451 | 0.81 | NPC1 (0.57) | NR1I3MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL13783463 | 0.81 | NPC1 (0.60) | MAPTNPC1RAB9AALDH1A1GAA | |
| SCHEMBL13783462 | 0.79 | CA12 (0.49) | CA12CA1CA9CYP17A1NR1I3 | |
| SCHEMBL29986825 | 0.79 | ITGB3 (0.47) | CA12CA1CA9NR1I3MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GGT1, VHL | CA12 941/4885CA1 1066/4885CA9 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.